Study of the Efficacy of Darbepoetin Alfa in the Treatment of Renal Anemia

Inclusion Criteria: * Patients on continuous ambulatory peritoneal dialysis * Patients receiving subcutaneous recombinant human erythropoietin (rHuEPO) * Patients with haemoglobin level ?10 g/dL and remain stable for the past 3 months while receiving rHuEPO Exclusion Criteria: * Uncontrolled hypertension * Severe congestive heart failure (NYHA class III or IV) * Grand mal epilepsy * Any kind of blood loss causing Fe depletion * Presence of infection, either acute or chronic, or inflammatory conditions within 3 months preceding the study * Malignancy * Aluminum toxicity * Severe hyperparathyroidism with marrow fibrosis or osteitis fibrosa \_ PTH \> 20 times of normal * Vitamin B12 or folate deficiency \_ MCV \> 100fL * Haemolysis * Marrow dysfunction e.g. aplastic anaemia, myelodysplastic syndrome, multiple myeloma, etc * Thalassaemia major, intermediate or minor, or red cell enzyme defects * Blood transfusion within 3 months preceding the study * Pregnancy or lactating mothers